Compare ASKA Pharmaceutical Holdings Co., Ltd. with Similar Stocks
Dashboard
1
The company has declared Negative results for the last 7 consecutive quarters
- INTEREST(9M) At JPY 113 MM has Grown at 41.25%
- NET SALES(HY) At JPY 16,641 MM has Grown at -47.76%
- ROCE(HY) Lowest at 0%
2
With ROE of 7.76%, it has a attractive valuation with a 0.99 Price to Book Value
3
Below par performance in long term as well as near term
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.62%
0%
-30.62%
6 Months
-16.05%
0%
-16.05%
1 Year
-11.64%
0%
-11.64%
2 Years
-2.68%
0%
-2.68%
3 Years
20.13%
0%
20.13%
4 Years
71.88%
0%
71.88%
5 Years
108.93%
0%
108.93%
ASKA Pharmaceutical Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.67%
EBIT Growth (5y)
4.76%
EBIT to Interest (avg)
96.24
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.86
Tax Ratio
19.54%
Dividend Payout Ratio
31.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.86%
ROE (avg)
11.79%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.99
EV to EBIT
15.81
EV to EBITDA
10.06
EV to Capital Employed
0.99
EV to Sales
1.09
PEG Ratio
1.37
Dividend Yield
NA
ROCE (Latest)
6.26%
ROE (Latest)
7.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
0.00
17,641.00
-100.00%
Operating Profit (PBDIT) excl Other Income
0.00
2,063.00
-100.00%
Interest
0.00
51.00
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
532.00
1,344.00
-60.42%
Operating Profit Margin (Excl OI)
0.00%
83.80%
-8.38%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -100.00% vs 7.88% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -60.42% vs 5.58% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
71,127.00
64,139.00
10.90%
Operating Profit (PBDIT) excl Other Income
8,919.00
7,580.00
17.66%
Interest
222.00
51.00
335.29%
Exceptional Items
-148.00
-300.00
50.67%
Consolidate Net Profit
5,625.00
5,101.00
10.27%
Operating Profit Margin (Excl OI)
82.00%
83.10%
-0.11%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 10.90% vs 2.06% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 10.27% vs -32.39% in Mar 2025
About ASKA Pharmaceutical Holdings Co., Ltd. 
ASKA Pharmaceutical Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






